From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct

Simple item page
dc.contributor.authorGonzález Gascón y Marín, Isabel
dc.contributor.authorMuñoz Novas, Carolina
dc.contributor.authorRodríguez Vicente, Ana-Eugenia
dc.contributor.authorQuijada Álamo, Miguel
dc.contributor.authorHernández Sánchez, María
dc.contributor.authorPérez Carretero, Claudia
dc.contributor.authorRamos Ascanio, Victoria
dc.contributor.authorHernández Rivas, José Ángel
dc.date.accessioned2023-06-17T08:23:04Z
dc.date.available2023-06-17T08:23:04Z
dc.date.issued2021-04-08
dc.description.abstracthronic lymphocytic leukemia (CLL) is an extremely heterogeneous disease. With the advent of oral targeted agents (Tas) the treatment of CLL has undergone a revolution, which has been accompanied by an improvement in patient’s survival and quality of life. This paradigm shift also affects the value of prognostic and predictive biomarkers and prognostic models, most of them inherited from the chemoimmunotherapy era but with a different behavior with Tas. This review discusses: (i) the role of the most relevant prognostic and predictive biomarkers in the setting of Tas; and (ii) the validity of classic and new scoring systems in the context of Tas. In addition, a critical point of view about predictive biomarkers with special emphasis on 11q deletion, novel resistance mutations, TP53 abnormalities, IGHV mutational status, complex karyotype and NOTCH1 mutations is stated. We also go over prognostic models in early stage CLL such as IPS-E. Finally, we provide an overview of the applicability of the CLL-IPI for patients treated with Tas, as well as the emergence of new models, generated with data from patients treated with Tas.
dc.description.departmentDepto. de Medicina
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.sponsorshipInstituto de Salud Carlos III (ISCIII)/ FEDER
dc.description.sponsorshipJunta de Castilla y León
dc.description.statuspub
dc.eprint.idhttps://eprints.ucm.es/id/eprint/70923
dc.identifier.doi10.3390/cancers13081782
dc.identifier.issn2072-6694
dc.identifier.officialurlhttps://doi.org/10.3390/cancers13081782
dc.identifier.relatedurlhttps://www.mdpi.com/2072-6694/13/8/1782/htm
dc.identifier.urihttps://hdl.handle.net/20.500.14352/6887
dc.issue.number8
dc.journal.titleCancers
dc.language.isoeng
dc.page.initial1782
dc.publisherMPDI
dc.relation.projectIDPI15/01471, PI18/01500
dc.relation.projectID(SA271P18, SA118P20)
dc.rightsAtribución 3.0 España
dc.rights.accessRightsopen access
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/es/
dc.subject.keywordchronic lymphocytic leukemia
dc.subject.keywordprognosis
dc.subject.keywordtargeted therapy
dc.subject.ucmHematología
dc.subject.ucmOncología
dc.subject.unesco3205.04 Hematología
dc.subject.unesco3201.01 Oncología
dc.titleFrom Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct
dc.typejournal article
dc.volume.number13
dspace.entity.typePublication
relation.isAuthorOfPublicationa4a145b6-73fb-465c-9c1b-969175cd85bd
relation.isAuthorOfPublication21c499fb-f6d9-4d2d-9309-7129512bf04d
relation.isAuthorOfPublication.latestForDiscoverya4a145b6-73fb-465c-9c1b-969175cd85bd
Download
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
cancers-13-01782.pdf
Size:
883.1 KB
Format:
Adobe Portable Document Format
downoload Download
Collections
Artículos